Cargando…
Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study
PURPOSE: Real‐world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE‐J validated claims‐based algorithms for selected cancers in Japan. METHODS: VALIDATE‐J was a multicenter, cross‐sectional, retr...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453514/ https://www.ncbi.nlm.nih.gov/pubmed/33960542 http://dx.doi.org/10.1002/pds.5263 |
_version_ | 1784570288880484352 |
---|---|
author | de Luise, Cynthia Sugiyama, Naonobu Morishima, Toshitaka Higuchi, Takakazu Katayama, Kayoko Nakamura, Sho Chen, Haoqian Nonnenmacher, Edward Hase, Ryota Jinno, Sadao Kinjo, Mitsuyo Suzuki, Daisuke Tanaka, Yoshiya Setoguchi, Soko |
author_facet | de Luise, Cynthia Sugiyama, Naonobu Morishima, Toshitaka Higuchi, Takakazu Katayama, Kayoko Nakamura, Sho Chen, Haoqian Nonnenmacher, Edward Hase, Ryota Jinno, Sadao Kinjo, Mitsuyo Suzuki, Daisuke Tanaka, Yoshiya Setoguchi, Soko |
author_sort | de Luise, Cynthia |
collection | PubMed |
description | PURPOSE: Real‐world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE‐J validated claims‐based algorithms for selected cancers in Japan. METHODS: VALIDATE‐J was a multicenter, cross‐sectional, retrospective study. Disease‐identifying algorithms were used to identify cancers diagnosed between January or March 2012 and December 2016 using claims data from two hospitals in Japan. Positive predictive values (PPVs), specificity, and sensitivity were calculated for prevalent (regardless of baseline cancer‐free period) and incident (12‐month cancer‐free period; with claims and registry periods in the same month) cases, using hospital cancer registry data as gold standard. RESULTS: 22 108 cancers were identified in the hospital claims databases. PPVs (number of registry cases) for prevalent/incident cases were: any malignancy 79.0% (25 934)/73.1% (18 119); colorectal 84.4% (3519)/65.6% (2340); gastric 87.4% (3534)/76.8% (2279); lung 88.1% (2066)/79.9% (1636); breast 86.4% (4959)/59.9% (3185); pancreatic 87.1% (582)/80.4% (508); melanoma 48.7% (46)/42.9% (36); and lymphoma 83.6% (1457)/77.8% (1035). Specificity ranged from 98.3% to 100% (prevalent)/99.5% to 100% (incident); sensitivity ranged from 39.1% to 67.6% (prevalent)/12.5% to 31.4% (incident). PPVs of claims‐based algorithms for several cancers in patients ≥66 years of age were slightly higher than those in a US Medicare population. CONCLUSIONS: VALIDATE‐J demonstrated high specificity and modest‐to‐moderate sensitivity for claims‐based algorithms of most malignancies using Japanese claims data. Use of claims‐based algorithms will enable identification of patient populations from claims databases, while avoiding direct patient identification. Further research is needed to confirm the generalizability of our results and applicability to specific subgroups of patient populations. |
format | Online Article Text |
id | pubmed-8453514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84535142021-09-27 Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study de Luise, Cynthia Sugiyama, Naonobu Morishima, Toshitaka Higuchi, Takakazu Katayama, Kayoko Nakamura, Sho Chen, Haoqian Nonnenmacher, Edward Hase, Ryota Jinno, Sadao Kinjo, Mitsuyo Suzuki, Daisuke Tanaka, Yoshiya Setoguchi, Soko Pharmacoepidemiol Drug Saf Original Articles PURPOSE: Real‐world data from large administrative claims databases in Japan have recently become available, but limited evidence exists to support their validity. VALIDATE‐J validated claims‐based algorithms for selected cancers in Japan. METHODS: VALIDATE‐J was a multicenter, cross‐sectional, retrospective study. Disease‐identifying algorithms were used to identify cancers diagnosed between January or March 2012 and December 2016 using claims data from two hospitals in Japan. Positive predictive values (PPVs), specificity, and sensitivity were calculated for prevalent (regardless of baseline cancer‐free period) and incident (12‐month cancer‐free period; with claims and registry periods in the same month) cases, using hospital cancer registry data as gold standard. RESULTS: 22 108 cancers were identified in the hospital claims databases. PPVs (number of registry cases) for prevalent/incident cases were: any malignancy 79.0% (25 934)/73.1% (18 119); colorectal 84.4% (3519)/65.6% (2340); gastric 87.4% (3534)/76.8% (2279); lung 88.1% (2066)/79.9% (1636); breast 86.4% (4959)/59.9% (3185); pancreatic 87.1% (582)/80.4% (508); melanoma 48.7% (46)/42.9% (36); and lymphoma 83.6% (1457)/77.8% (1035). Specificity ranged from 98.3% to 100% (prevalent)/99.5% to 100% (incident); sensitivity ranged from 39.1% to 67.6% (prevalent)/12.5% to 31.4% (incident). PPVs of claims‐based algorithms for several cancers in patients ≥66 years of age were slightly higher than those in a US Medicare population. CONCLUSIONS: VALIDATE‐J demonstrated high specificity and modest‐to‐moderate sensitivity for claims‐based algorithms of most malignancies using Japanese claims data. Use of claims‐based algorithms will enable identification of patient populations from claims databases, while avoiding direct patient identification. Further research is needed to confirm the generalizability of our results and applicability to specific subgroups of patient populations. John Wiley & Sons, Inc. 2021-06-01 2021-09 /pmc/articles/PMC8453514/ /pubmed/33960542 http://dx.doi.org/10.1002/pds.5263 Text en © 2021 Pfizer Inc. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles de Luise, Cynthia Sugiyama, Naonobu Morishima, Toshitaka Higuchi, Takakazu Katayama, Kayoko Nakamura, Sho Chen, Haoqian Nonnenmacher, Edward Hase, Ryota Jinno, Sadao Kinjo, Mitsuyo Suzuki, Daisuke Tanaka, Yoshiya Setoguchi, Soko Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study |
title | Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study |
title_full | Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study |
title_fullStr | Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study |
title_full_unstemmed | Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study |
title_short | Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study |
title_sort | validity of claims‐based algorithms for selected cancers in japan: results from the validate‐j study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453514/ https://www.ncbi.nlm.nih.gov/pubmed/33960542 http://dx.doi.org/10.1002/pds.5263 |
work_keys_str_mv | AT deluisecynthia validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT sugiyamanaonobu validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT morishimatoshitaka validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT higuchitakakazu validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT katayamakayoko validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT nakamurasho validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT chenhaoqian validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT nonnenmacheredward validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT haseryota validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT jinnosadao validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT kinjomitsuyo validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT suzukidaisuke validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT tanakayoshiya validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy AT setoguchisoko validityofclaimsbasedalgorithmsforselectedcancersinjapanresultsfromthevalidatejstudy |